Advertisement
Research Article| Volume 7, ISSUE 3, P551-566, September 1987

Monitoring Cyclic Antidepressants

  • C. Lindsay DeVane
    Correspondence
    University of Florida, College of Pharmacy, Box J-486, Gainesville, Florida 32610
    Affiliations
    Associate Professor of Pharmacy and Psychiatry, Colleges of Pharmacy and Medicine, University of Florida, Gainesville
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30731-5
Monitoring Cyclic Antidepressants
Previous ArticleLithium Monitoring
Next ArticleNewer Cardiae Agents: Antiarrhythmics and Antianginal Agents
      This paper is only available as a PDF. To read, Please Download here.
      Therapeutic drug monitoring of antidepressants can ensure that a reasonable amount of drug reached the circulation, can aid in dosage adjustments for treating endogenous depression, can avoid toxicity, and aid in the diagnosis of drug-induced delirium. This article reviews the justification for antidepressant monitoring, discusses sample collection procedures, and presents guidelines for the interpretation of data.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abernethy D.R.
        • Greenblatt D.J.
        • Divoll M.
        • et al.
        Interaction of cimetidine with the triazolobenzodiazepines, alprazolam, and triazolam.
        Psychopharmacology (Berlin). 1983; 80: 275-278
        • Abernethy D.R.
        • Greenblatt D.J.
        • Shader R.I.
        Plasma levels of trazodone: Methodology and applications.
        Pharmacology. 1984; 28: 42-46
        • Abernethy D.R.
        • Greenblatt D.J.
        • Shader R.I.
        Trimipramine kinetics and absolute bioavailability: Use of gas-liquid chromatography with nitrogen-phosphorus detection.
        Clin Pharmacol Ther. 1984; 35: 348-353
        • Alexanderson B.
        Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses—a cross-over study.
        Eur J Clin Pharmacol. 1972; 5: 1-10
        • Alkalay D.
        • Wagner Jr, W.E.
        • Carsen S.
        • et al.
        Bioavailability and kinetics of maprotiline.
        Clin Pharmacol Ther. 1980; 27: 697-703
        • Aronoff G.R.
        • Bergstrom R.F.
        • Pottratz S.T.
        • et al.
        Fluoxetine kinetics and protein binding in normal and impaired renal function.
        Clin Pharmacol Ther. 1978; 23: 573-579
        • Bickel M.H.
        Poisoning by tricyclic antidepressant drugs: General and pharmacokinetic considerations.
        Int J Clin Pharmacol. 1975; 11: 145-176
        • Bayer A.J.
        • Pathy M.S.J.
        • Ankier S.I.
        Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly.
        Br J Clin Pharmacol. 1983; 16: 371-376
        • Bjerre M.
        • Gram L.F.
        • Kragh-Sorensen P.
        • et al.
        Dose-dependent kinetics of imipramine in elderly patients.
        Psychopharmacology (Berlin). 1981; 75: 354-357
        • Borga O.
        • Azarnoff D.L.
        • Plymforshell G.
        • et al.
        Plasma protein binding of tricyclic antidepressants in man.
        Biochem Pharmacol. 1969; 18: 2141-2142
        • Borga O.
        • Piafsky K.M.
        • Nilsen O.G.
        Plasma protein binding of basic drugs. I. Selective displacement from alpha-1-acid glycoprotein by tris(2-butoxyethyl) phosphate.
        Clin Pharmacol Ther. 1977; 22: 539-544
        • Cooper T.B.
        Plasma level monitoring of antipsychotic drugs.
        Clin Pharmacokinet. 1978; 3: 14-38
        • Curry SH.
        Commentary: The strategy and value of neuroleptic drug monitoring.
        J Clin Psychopharmacol. 1986; 5: 263-271
        • Dawling S.
        • Braithwaite R.A.
        • McAuley R.
        • et al.
        Single oral dose pharmacokinetics of clomipramine in depressed patients.
        Postgrad Med J. 1980; 56: 115-116
        • Dawling S.
        • Crome P.
        • Braithwaite R.
        Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers.
        Clin Pharmacokinet. 1980; 5: 394-401

      16. DeVane CL: Naming the cyclic antidepressants. J Clin Psychopharmacol, in press

        • DeVane C.L.
        • Jusko W.J.
        Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine.
        Drug Inteil Clin Pharm. 1981; 15: 263-266
        • DeVane C.L.
        • Savett M.
        • Jusko W.J.
        Desipramine and 2-hydroxy desipramine pharmacokinetics in normal volunteers.
        Eur J Clin Pharmacol. 1981; 19: 61-64
        • DeVane C.L.
        • Wolin R.E.
        • Rovere R.A.
        • et al.
        Excessive plasma concentrations of tricyclic antidepressants resulting from usual doses.
        J Clin Psychiatry. 1981; 42: 143-147
        • DeVane C.L.
        • Simpkins J.W.
        • Stout S.A.
        Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat.
        Psychopharmacology (Berlin). 1984; 84: 225-230
        • Dieterle W.
        • Faigle J.W.
        • Kung W.
        • et al.
        The metabolic fate of C-14-oxaprotiline in man. Stereospecific disposition.
        Biopharm Drug Dispos. 1984; 5: 377-386
        • Glassman A.H.
        • Bigger J.T.
        • Giardina E.V.
        • et al.
        Clinical characteristics of imipramine-induced orthostatic hypotension.
        Lancet. 1979; 1: 468-472
        • Glassman A.H.
        • Schildkraut J.J.
        • Orsulak P.J.
        • et al.
        Tricyclic antidepressant blood level measurements and clinical outcome: An APA task force report.
        Am J Psychiatry. 1985; 142: 155-163

      24. Golden RB, DeVane CL, Laizure SC, et al: Bupropion: The role of metabolites in clinical outcome. Arch Gen Psychiatry, in press

        • Gram L.F.
        • Overo K.F.
        First-pass metabolism of nortriptyline in man.
        Clin Pharmacol Ther. 1975; 18: 305-314
        • Gram L.F.
        • Anderson P.B.
        • Overo K.F.
        • et al.
        Comparison of single dose kinetics of imipramine, nortriptyline, and antipyrine in man.
        Psychopharmacology (Berlin). 1976; 50: 21-27
        • Gram L.F.
        • Pedersen O.L.
        • Kristensen C.B.
        • et al.
        Drug level monitoring in psychopharmacology: Usefulness and clinical problems, with reference to tricyclic antidepressants.
        Ther Drug Monit. 1982; 4: 17-25
        • Hollister L.E.
        Monitoring tricyclic antidepressant plasma concentrations.
        JAMA. 1979; 241: 2530-2533
        • Hrdina P.D.
        • Rovei V.
        • Henry J.F.
        • et al.
        Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly.
        Psychopharmacology (Berlin). 1980; 70: 29-34
        • Hullett F.J.
        • Levy A.B.
        • Tachiki K.H.
        Serum imipramine concentrations lower than plasma values.
        J Clin Psychiatry. 1984; 45: 516-518
        • Jorgensen A.
        • Hanson V.
        Pharmacokinetics of amitriptyline infused intravenously in man.
        Eur J Clin Pharmacol. 1976; 10: 337-341
        • Kinney J.L.
        • Evans Jr, R.L.
        Evaluation of amoxapine.
        Clin Pharm. 1982; 1: 417-424
        • Lai A.A.
        • Schroeder D.H.
        Clinical pharmacokinetics of bupropion: A review.
        J Clin Psychiatry. 1983; 44: 82-84
        • Laizure S.C.
        • DeVane C.L.
        The stability of bupropion and its major metabolites in human plasma under varying storage conditions.
        Ther Drug Monit. 1985; 7: 447-450
        • Linnoila M.
        • Dorrity F.
        • Jobson K.
        Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients.
        Am J Psychiatry. 1978; 135: 557-561
        • Moody J.P.
        • Whyte S.F.
        • MacDonald A.J.
        • et al.
        Pharmacokinetics aspects of protriptyline plasma levels.
        Eur J Clin Pharmacol. 1977; 11: 51-56
        • Nelson J.C.
        • Jatlow P.I.
        • Bock J.
        • et al.
        Major adverse reactions during desipramine treatment: Relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics.
        Arch Gen Psychiatry. 1982; 39: 1055-1061
        • Norman T.R.
        • Burrows G.D.
        Benzodiazepine plasma concentrations and anxiolytic response.
        in: Burrows G.D. Norman T.R. Davies B. Antianxiety Agents: Drugs in Psychiatry, Volume 2. Elsevier, New York1984: 93-105
        • Orsulak P.J.
        • Sink M.
        • Weed J.
        Blood collection tubes for tricyclic antidepressant drugs: A reevaluation.
        Ther Drug Monit. 1984; 6: 444-448
        • Orsulak P.J.
        • Gerson B.
        Clinical laboratory quality control: Application to analysis of tricyclic antidepressants.
        in: Usdin E. Clinical Pharmacology in Psychiatry. Elsevier, New York1981: 43-57
        • Orsulak P.J.
        Therapeutic monitoring of antidepressant drugs: Current methodology and applications.
        J Clin Psychiatry. 1986; 47: 39-50
        • Petit J.M.
        • Spiker D.G.
        • Ruwitch J.E.
        • et al.
        Tricyclic antidepressant plasma levels and adverse effects after overdose.
        Clin Pharmacol Ther. 1977; 21: 47-51
        • Piafsky K.M.
        • Borga O.
        Plasma protein binding of basic drugs. II. Importance of alpha-1-acid glycoprotein to interindividual variation.
        Clin Pharmacol Ther. 1977; 22: 545-549
        • Preskorn S.H.
        Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach.
        J Clin Psychiatry. 1986; 47: 24-30
        • Preskorn S.H.
        • Simpson S.
        Tricyclic-antidepressant-induced delirium and plasma drug concentration.
        Am J Psychiatry. 1982; 139: 822-823
        • Risch S.C.
        • Huey L.Y.
        • Janowsky D.S.
        Plasma levels of tricyclic antidepressants and clinical efficacy: Review of the literature—Parts I and II.
        J Clin Psychiatry. 1979; 40 (58-89): 4-16
        • Scoggins B.A.
        • Maguire K.P.
        • Norman T.R.
        • et al.
        Measurement of tricyclic antidepressants. Part I. A review of methodology.
        Clin Chem. 1980; 26: 5-17
        • Shami M.
        • Elliott H.L.
        • Kelman A.W.
        • et al.
        The pharmacokinetics of mianserin.
        Br J Clin Pharmacol. 1983; 15: 313S-322S
        • Shopsin B.
        Second generation antidepressants.
        J Clin Psychiatry. 1980; 41 (Sec 2, 45-56): 12
        • Sillanpaa M.
        Carbamazepine: Pharmacology and clinical uses.
        Acta Neurol Scand 64(Suppl. 1981; 88: 1-177
        • Sulser F.
        • Vetulani J.
        • Mobley P.L.
        Mode of action of antidepressant drugs.
        Biochem Pharmacol. 1978; 27: 257-261
        • Sutfin T.A.
        • DeVane C.L.
        • Jusko W.J.
        The analysis and disposition of imipramine and its active metabolites in man.
        Psychopharmacology (Berlin). 1984; 82: 310-317
        • Ziegler V.E.
        • Biggs J.T.
        • Wylie L.T.
        • et al.
        Doxepin kinetics.
        Clin Pharmacol Ther. 1978; 23: 573-579
        • Ziegler V.E.
        • Biggs J.T.
        • Wylie L.T.
        • et al.
        Protriptyline kinetics.
        Clin Pharmacol Ther. 1978; 23: 580-584

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30731-5

      Copyright

      © 1987 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX